Clinical trial · Observational
Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary Objective * To investigate and clearly document the presence and extent of cognitive decline, if any, in women of Asian origin following standard-dose systematic adjuvant chemotherapy for the treatment of breast cancer * Investigation and establishment of a relationship between degree of oxidative DNA and lipid damage as indicated by plasma and urinary biochemical markers. Secondary Objective • To validate the use of hydrogen peroxide and serum amyloid as biomarkers of damage
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Breast Cancer | Breast Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Early breast cancer
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically documented breast cancer 2. Females greater than 18 years old 3. Eastern Cooperative Oncology Group (ECOG) Performance status 0,1,2 4. Requires to undergo standard-dose systemic adjuvant chemotherapy 5. Patients must be informed of nature of study and sign an informed consent form Exclusion criteria a. Dementia/significantly altered mental status that will prohibit the understanding and/or giving of informed consent
References
Publications (0)
Data not yet available